Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAM561 in newly diagnosed glioblastoma
NCT04250922Phase 3Active, not recruiting
- Sponsor
- Laminar Pharma
- Start
- Dec 2019
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial in glioblastoma (GBM) comparing Arm A: SoC + Placebo with Arm B: SoC + LAM561 (2 arms). Primary endpoints: Progression-Free Survival and Overall Survival. Started Dec 2019; status: active, not recruiting.
02
Drugs
2-hydroxyoleic acid
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04250922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04250922.